Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs

FREMONT, Calif.--(BUSINESS WIRE)--<a href="" target="_blank">#biotech</a>--Verseon presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia. These drug candidates could become the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of vision loss. “Our oral development candidate has the potential to redefine how DME is treated,” said Dr. Anirban Datta, Verseon’s Senior Director of Discovery Biology. “Not o

Full Story →